Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IMMUNIC, INC.VTL · Entity 6306 | Director · Co-Chairman and CEO | June 14, 2017 | June 15, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IMMUNIC, INC.
Report date June 14, 2017 · Filed June 15, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 194,966 |
Reported balance
After 2017-06-14 transaction · row 1
1 source rowRow 1 · 2017-06-14 · Purchase · Acquired 10,000 · Balance 194,966 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.075 to $3.10. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price range set forth in this footnote (1) to this Form 4. |
| Common StockSEC Table I · non-derivative | IndirectBy trust | 119,964 |
Reported balance
Holding disclosure · report date 2017-06-14 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 119,964 |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.075 to $3.10. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price range set forth in this footnote (1) to this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 14, 2017 Filed Jun 15, 2017 20:28 UTC | IMMUNIC, INC. VTL · Entity 6306 | PurchaseCommon Stock | 10,000 | $3.10 | $30,981.00 |
DisclosureSEC source: 0001280776-17-000074 · wf-form4_149755850136766.xml · nonDerivative · entry 1 Winters Terence E. · CIK 0001591099 · Director · Co-Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,966 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.075 to $3.10. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price range set forth in this footnote (1) to this Form 4. Read SEC document |
| June 10, 2017 Filed Jun 14, 2017 00:16 UTC | IMMUNIC, INC. VTL · Entity 6306 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001280776-17-000070 · wf-form4_149739935757762.xml · derivative · entry 1 Winters Terence E. · CIK 0001591099 · Director · Co-Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2027-06-09 F1 · derivative.exercise_date: One forty-eighth (1/48th) of the shares of common stock subject to the option shall vest monthly beginning on July 10, 2017, such that all of the shares of common stock subject to the option are vested by June 10, 2021, subject to the reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan (the "Plan")) through each vesting date; provided, that, 100% of the unvested portion of the option, if any, shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.